Discussion
Diagnosis With Brief Discussion
- Diagnosis
- NUT Carcinoma
- Radiologic Findings
- Fig 1. Chest radiograph shows dense consolidation in left lower lobe with pleural effusion in left hemithorax
Fig 2. Contrast enhanced chest CT image shows arterial enhancing lobulated contoured mass in left lower lobe, with necrosis and atelectasis of left lower lobe.
Fig 3. Contrast enhanced chest CT image shows enlarged된 necrotized lymph nodes in subcarinal, Lt. hilar areas.
Fig 4. Contrast enhanced chest CT image shows enhancing lobulated contoured nodules in left pleura
- Brief Review
- Nuclear protein in testis (NUT) carcinoma is a rare, highly lethal malignancy characterized by genetic alterations in the NUTM1 gene. Typically, NUT carcinoma arises in squamous cells along the body's midline organs (head, neck, lungs), yet non-midline organ origins are also reported. The precise incidence of NUT carcoinoma remains undefined. A systematic review of 119 NUT carcinoma reported that nearly 50% of patients were adolescents or young adults (14–30 yrs), however it can occur in any age. Clinical presentation of NUT carcinoma also lacks specificity since the distribution is not strictly confined to midline organs, and it shows rapid growth, often over primarily related organs. Also, NUT is shows lack of pathognomonic histologic features due to its poor differentiation. Therefore it is suggested that if rapidly progressing tumor masses are found in midline regions such as the head/neck and thoracic cavity on imaging, NC should be given priority consideration and confirmed by timely biopsy, with recommendation of NUT IHC as an initial screening. There is no standard treatment for NUT carcinomas, with median survivial of 6.5–10.6 months
- References
- 1. Yu Zhang, Qi Zhang, Yue Hao et al. International guidelines on the diagnosis and treatment of NUT carcinoma. The Innovation 7(1): 101068, January 5, 2026
2. Jiaqian Yuan, Zhili Xu, Yong Guo et al. Diagnosis, Treatment and Prognosis of Primary Pulmonary NUT Carcinoma: A Literature Review Curr Oncol. 2022 Sep 22;29(10):6807–6815.
- Keywords